spironolactone has been researched along with Epilepsy in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The combination of AGLD (5 mg/kg) with phenobarbital (PB, applied at its subeffective dose of 15 mg/kg) significantly shortened motor seizure and afterdischarge duration in amygdala-kindled seizures." | 7.73 | Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats. ( Borowicz, KK; Czuczwar, SJ, 2005) |
| " The combination of AGLD (5 mg/kg) with phenobarbital (PB, applied at its subeffective dose of 15 mg/kg) significantly shortened motor seizure and afterdischarge duration in amygdala-kindled seizures." | 3.73 | Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats. ( Borowicz, KK; Czuczwar, SJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, EL | 1 |
| Kaplan, PW | 1 |
| Borowicz, KK | 1 |
| Czuczwar, SJ | 1 |
| Ross, FM | 1 |
| Gwyn, P | 1 |
| Spanswick, D | 1 |
| Davies, SN | 1 |
| Mertin, J | 1 |
| Simon, O | 1 |
| Schmiedek, P | 1 |
1 review available for spironolactone and Epilepsy
| Article | Year |
|---|---|
Caring for transgender patients with epilepsy.
Topics: Androgens; Anti-HIV Agents; Anticonvulsants; Antidepressive Agents; Anxiety Disorders; Comorbidity; | 2017 |
3 other studies available for spironolactone and Epilepsy
| Article | Year |
|---|---|
Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats.
Topics: Adrenergic Agents; Aminoglutethimide; Amygdala; Animals; Anticonvulsants; Clonazepam; Disease Models | 2005 |
Carbenoxolone depresses spontaneous epileptiform activity in the CA1 region of rat hippocampal slices.
Topics: Animals; Carbenoxolone; Depression, Chemical; Epilepsy; Female; Gap Junctions; Hippocampus; Hydrogen | 2000 |
The influence of aldosterone and anticonvulsant drugs on electroencephalographic and clinical disturbances induced by the spirolactone derivative, potassium canrenoate.
Topics: Aldosterone; Animals; Anticonvulsants; Brain; Diazepam; Disease Models, Animal; Dogs; Electroencepha | 1975 |